vs

Side-by-side financial comparison of EQUITY BANCSHARES INC (EQBK) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $63.5M, roughly 1.1× EQUITY BANCSHARES INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 34.8%, a 349.3% gap on every dollar of revenue. On growth, EQUITY BANCSHARES INC posted the faster year-over-year revenue change (28.4% vs 21.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 6.6%).

Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

EQBK vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.1× larger
RIGL
$69.8M
$63.5M
EQBK
Growing faster (revenue YoY)
EQBK
EQBK
+7.2% gap
EQBK
28.4%
21.2%
RIGL
Higher net margin
RIGL
RIGL
349.3% more per $
RIGL
384.0%
34.8%
EQBK
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
6.6%
EQBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EQBK
EQBK
RIGL
RIGL
Revenue
$63.5M
$69.8M
Net Profit
$22.1M
$268.1M
Gross Margin
91.5%
Operating Margin
41.7%
33.2%
Net Margin
34.8%
384.0%
Revenue YoY
28.4%
21.2%
Net Profit YoY
30.0%
1769.2%
EPS (diluted)
$1.07
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EQBK
EQBK
RIGL
RIGL
Q4 25
$63.5M
$69.8M
Q3 25
$18.0M
$69.5M
Q2 25
$58.4M
$101.7M
Q1 25
$60.6M
$53.3M
Q4 24
$58.3M
$57.6M
Q3 24
$55.3M
$55.3M
Q2 24
$55.4M
$36.8M
Q1 24
$55.9M
$29.5M
Net Profit
EQBK
EQBK
RIGL
RIGL
Q4 25
$22.1M
$268.1M
Q3 25
$-29.7M
$27.9M
Q2 25
$15.3M
$59.6M
Q1 25
$15.0M
$11.4M
Q4 24
$17.0M
$14.3M
Q3 24
$19.9M
$12.4M
Q2 24
$11.7M
$-1.0M
Q1 24
$14.1M
$-8.2M
Gross Margin
EQBK
EQBK
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
EQBK
EQBK
RIGL
RIGL
Q4 25
41.7%
33.2%
Q3 25
-207.2%
40.9%
Q2 25
31.5%
60.1%
Q1 25
31.1%
23.9%
Q4 24
35.0%
28.9%
Q3 24
43.1%
25.4%
Q2 24
29.4%
1.2%
Q1 24
31.8%
-23.6%
Net Margin
EQBK
EQBK
RIGL
RIGL
Q4 25
34.8%
384.0%
Q3 25
-164.7%
40.2%
Q2 25
26.1%
58.6%
Q1 25
24.8%
21.5%
Q4 24
29.1%
24.9%
Q3 24
35.9%
22.5%
Q2 24
21.1%
-2.8%
Q1 24
25.2%
-27.9%
EPS (diluted)
EQBK
EQBK
RIGL
RIGL
Q4 25
$1.07
$14.11
Q3 25
$-1.55
$1.46
Q2 25
$0.86
$3.28
Q1 25
$0.85
$0.63
Q4 24
$1.06
$0.82
Q3 24
$1.28
$0.70
Q2 24
$0.76
$-0.06
Q1 24
$0.90
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EQBK
EQBK
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$155.0M
Total DebtLower is stronger
$443.2M
$52.5M
Stockholders' EquityBook value
$732.1M
$391.5M
Total Assets
$6.4B
$513.6M
Debt / EquityLower = less leverage
0.61×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EQBK
EQBK
RIGL
RIGL
Q4 25
$155.0M
Q3 25
$137.1M
Q2 25
$108.4M
Q1 25
$77.1M
Q4 24
$77.3M
Q3 24
$61.1M
Q2 24
$49.1M
Q1 24
$49.5M
Total Debt
EQBK
EQBK
RIGL
RIGL
Q4 25
$443.2M
$52.5M
Q3 25
$486.9M
$60.0M
Q2 25
$448.4M
$60.0M
Q1 25
$376.9M
$60.0M
Q4 24
$312.8M
$60.0M
Q3 24
$437.5M
$60.0M
Q2 24
$391.7M
$60.0M
Q1 24
$367.1M
$60.0M
Stockholders' Equity
EQBK
EQBK
RIGL
RIGL
Q4 25
$732.1M
$391.5M
Q3 25
$711.9M
$117.6M
Q2 25
$635.6M
$81.9M
Q1 25
$617.3M
$18.6M
Q4 24
$592.9M
$3.3M
Q3 24
$504.0M
$-14.6M
Q2 24
$461.4M
$-29.9M
Q1 24
$456.8M
$-31.7M
Total Assets
EQBK
EQBK
RIGL
RIGL
Q4 25
$6.4B
$513.6M
Q3 25
$6.4B
$242.5M
Q2 25
$5.4B
$206.7M
Q1 25
$5.4B
$176.0M
Q4 24
$5.3B
$164.0M
Q3 24
$5.4B
$139.4M
Q2 24
$5.2B
$128.4M
Q1 24
$5.2B
$126.5M
Debt / Equity
EQBK
EQBK
RIGL
RIGL
Q4 25
0.61×
0.13×
Q3 25
0.68×
0.51×
Q2 25
0.71×
0.73×
Q1 25
0.61×
3.23×
Q4 24
0.53×
18.25×
Q3 24
0.87×
Q2 24
0.85×
Q1 24
0.80×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EQBK
EQBK
RIGL
RIGL
Operating Cash FlowLast quarter
$51.4M
$22.0M
Free Cash FlowOCF − Capex
$38.1M
FCF MarginFCF / Revenue
60.0%
Capex IntensityCapex / Revenue
20.9%
Cash ConversionOCF / Net Profit
2.33×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$88.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EQBK
EQBK
RIGL
RIGL
Q4 25
$51.4M
$22.0M
Q3 25
$8.5M
$24.0M
Q2 25
$28.3M
$30.5M
Q1 25
$21.7M
$-893.0K
Q4 24
$73.8M
$14.5M
Q3 24
$23.5M
$21.7M
Q2 24
$16.0M
$302.0K
Q1 24
$12.6M
$-5.0M
Free Cash Flow
EQBK
EQBK
RIGL
RIGL
Q4 25
$38.1M
Q3 25
$4.5M
Q2 25
$26.0M
Q1 25
$20.2M
Q4 24
$65.4M
Q3 24
$19.7M
Q2 24
$15.2M
Q1 24
$10.6M
FCF Margin
EQBK
EQBK
RIGL
RIGL
Q4 25
60.0%
Q3 25
24.7%
Q2 25
44.5%
Q1 25
33.3%
Q4 24
112.1%
Q3 24
35.6%
Q2 24
27.4%
Q1 24
19.0%
Capex Intensity
EQBK
EQBK
RIGL
RIGL
Q4 25
20.9%
Q3 25
22.3%
Q2 25
3.9%
Q1 25
2.4%
Q4 24
14.6%
Q3 24
6.8%
Q2 24
1.5%
Q1 24
3.6%
Cash Conversion
EQBK
EQBK
RIGL
RIGL
Q4 25
2.33×
0.08×
Q3 25
0.86×
Q2 25
1.85×
0.51×
Q1 25
1.44×
-0.08×
Q4 24
4.35×
1.01×
Q3 24
1.18×
1.75×
Q2 24
1.37×
Q1 24
0.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons